Testing rapid antibiotic susceptibility for patients with bacteremia
Impact of Performing a Rapid Antibiotic Susceptibility Test (MHR-SIR) on Antibiotic Therapy Adaptation in Adult Patients with Enterobacterales Bacteremia, Controlled, Randomized Cluster and Cross-over Study
This study tests if quickly finding out which antibiotics work best can help hospitalized adults with blood infections get the right treatment faster.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 960 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondation Hôpital Saint-Joseph Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT06425367 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of rapid antibiotic susceptibility testing on the adaptation of antibiotic therapy in adult patients diagnosed with bacteremia caused by Enterobacterales. It aims to initiate effective antibiotic treatment promptly after blood cultures are taken, utilizing a rapid diagnostic approach to determine the most effective antibiotics. The study will involve hospitalized patients with positive blood cultures and will assess how quickly and effectively antibiotic therapy can be adjusted based on susceptibility results.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are hospitalized with bacteremia caused by Enterobacterales.
Not a fit: Patients with non-enterobacterial bacteremia or those who are pregnant, breastfeeding, or under legal protection may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and targeted antibiotic treatments for patients with bacteremia, potentially improving outcomes and reducing the risk of septic shock.
How similar studies have performed: Other studies have shown that rapid diagnostic tests can significantly improve antibiotic therapy outcomes, suggesting that this approach has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \>= 18 * Patient hospitalized in a clinical department of each participating center * Patient managed in the context of bacteremia (microbiological criterion = positive blood culture) * Patient with positive blood culture for Enterobacterales * Patient affiliated to a health insurance scheme * Patient/relative having given free, informed and express oral consent Exclusion Criteria: * Patients with non-enterobacterial bacteremia * Patient under guardianship * Patient deprived of liberty * Patient under court protection * Pregnant or breast-feeding patient
Where this trial is running
Paris
- Hôpital Paris Saint Joseph — Paris, France (Recruiting)
Study contacts
- Principal investigator: Jean Claude NGUYEN VAN, MD — Fondation Hôpital Saint-Joseph
- Study coordinator: Helene BEAUSSIER
- Email: crc@ghpsj.fr
- Phone: +33144127038
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.